Literature DB >> 18768415

Sodium bicarbonate vs sodium chloride for the prevention of contrast medium-induced nephropathy in patients undergoing coronary angiography: a randomized trial.

Somjot S Brar1, Albert Yuh-Jer Shen, Michael B Jorgensen, Adam Kotlewski, Vicken J Aharonian, Natasha Desai, Michael Ree, Ahmed Ijaz Shah, Raoul J Burchette.   

Abstract

CONTEXT: Sodium bicarbonate has been suggested as a possible strategy for prevention of contrast medium-induced nephropathy, a common cause of renal failure associated with prolonged hospitalization, increased health care costs, and substantial morbidity and mortality.
OBJECTIVE: To determine if sodium bicarbonate is superior to sodium chloride for preventing contrast medium-induced nephropathy in patients with moderate to severe chronic kidney dysfunction who are undergoing coronary angiography. DESIGN, SETTING, AND PATIENTS: Randomized, controlled, single-blind study conducted between January 2, 2006, and January 31, 2007, and enrolling 353 patients with stable renal disease who were undergoing coronary angiography at a single US center. Included patients were 18 years or older and had an estimated glomerular filtration rate of 60 mL/min per 1.73 m(2) or less and 1 or more of diabetes mellitus, history of congestive heart failure, hypertension, or age older than 75 years.
INTERVENTIONS: Patients were randomized to receive either sodium chloride (n = 178) or sodium bicarbonate (n = 175) administered at the same rate (3 mL/kg for 1 hour before coronary angiography, decreased to 1.5 mL/kg per hour during the procedure and for 4 hours after the completion of the procedure). MAIN OUTCOME MEASURE: The primary end point was a 25% or greater decrease in the estimated glomerular filtration rate on days 1 through 4 after contrast exposure.
RESULTS: Median patient age was 71 (interquartile range, 65-76) years, and 45% had diabetes mellitus. The groups were well matched for baseline characteristics. The primary end point was met in 13.3% of the sodium bicarbonate group and 14.6% of the sodium chloride group (relative risk, 0.94; 95% confidence interval, 0.55-1.60; P = .82). In patients randomized to receive sodium bicarbonate vs sodium chloride, the rates of death, dialysis, myocardial infarction, and cerebrovascular events did not differ significantly at 30 days (1.7% vs 1.7%, 0.6% vs 1.1%, 0.6% vs 0%, and 0% vs 2.2%, respectively) or at 30 days to 6 months (0.6% vs 2.3%, 0.6% vs 1.1%, 0.6% vs 2.3%, and 0.6% vs 1.7%, respectively) (P > .10 for all).
CONCLUSION: The results of this study do not suggest that hydration with sodium bicarbonate is superior to hydration with sodium chloride for the prevention of contrast medium-induced nephropathy in patients with moderate to severe chronic kidney disease who are undergoing coronary angiography. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00312117.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18768415     DOI: 10.1001/jama.300.9.1038

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  74 in total

1.  Prevention of contrast-induced AKI--the ongoing saga.

Authors:  Usman Baber; Roxana Mehran
Journal:  Nat Rev Nephrol       Date:  2012-03-13       Impact factor: 28.314

Review 2.  Does bicarbonate prevent contrast-induced nephropathy in cardiovascular patients undergoing contrast imaging?

Authors:  Dilan Dabare; Mohammed Banihani; Paul Gibbs; Perbinder Grewal
Journal:  Interact Cardiovasc Thorac Surg       Date:  2013-08-30

Review 3.  Contrast-induced acute kidney injury and diabetic nephropathy.

Authors:  Andrew D Calvin; Sanjay Misra; Axel Pflueger
Journal:  Nat Rev Nephrol       Date:  2010-09-28       Impact factor: 28.314

4.  Guidelines on the use of iodinated contrast media in patients with kidney disease 2012: digest version : JSN, JRS, and JCS Joint Working Group.

Authors:  Iwao Ohno; Hiromitsu Hayashi; Kazutaka Aonuma; Masaru Horio; Naoki Kashihara; Hirokazu Okada; Yasuhiro Komatsu; Shozo Tamura; Kazuo Awai; Yasuyuki Yamashita; Ryohei Kuwatsuru; Atsushi Hirayama; Yoshihiko Saito; Toyoaki Murohara; Nagara Tamaki; Akira Sato; Tadateru Takayama; Enyu Imai; Yoshinari Yasuda; Daisuke Koya; Yoshiharu Tsubakihara; Shigeo Horie; Yukunori Korogi; Yoshifumi Narumi; Katsumi Hayakawa; Hiroyuki Daida; Koichi Node; Isao Kubota
Journal:  Clin Exp Nephrol       Date:  2013-08       Impact factor: 2.801

5.  Guidelines on the use of iodinated contrast media in patients with kidney disease 2012: digest version. JSN, JRS, and JCS Joint Working Group.

Authors:  Iwao Ohno; Hiromitsu Hayashi; Kazutaka Aonuma; Masaru Horio; Naoki Kashihara; Hirokazu Okada; Yasuhiro Komatsu; Shozo Tamura; Kazuo Awai; Yasuyuki Yamashita; Ryohei Kuwatsuru; Atsushi Hirayama; Yoshihiko Saito; Toyoaki Murohara; Nagara Tamaki; Akira Sato; Tadateru Takayama; Enyu Imai; Yoshinari Yasuda; Daisuke Koya; Yoshiharu Tsubakihara; Shigeo Horie; Yukunori Korogi; Yoshifumi Narumi; Katsumi Hayakawa; Hiroyuki Daida; Koichi Node; Isao Kubota
Journal:  Jpn J Radiol       Date:  2013-08       Impact factor: 2.374

Review 6.  Renal-related adverse effects of intravenous contrast media in computed tomography.

Authors:  Kheng Song Leow; Yi Wei Wu; Cher Heng Tan
Journal:  Singapore Med J       Date:  2015-04       Impact factor: 1.858

Review 7.  Contrast medium induced acute kidney injury: a narrative review.

Authors:  Valentina Pistolesi; Giuseppe Regolisti; Santo Morabito; Ilaria Gandolfini; Silvia Corrado; Giovanni Piotti; Enrico Fiaccadori
Journal:  J Nephrol       Date:  2018-05-25       Impact factor: 3.902

8.  Guideline on the use of iodinated contrast media in patients with kidney disease 2018.

Authors:  Yoshitaka Isaka; Hiromitsu Hayashi; Kazutaka Aonuma; Masaru Horio; Yoshio Terada; Kent Doi; Yoshihide Fujigaki; Hideo Yasuda; Taichi Sato; Tomoyuki Fujikura; Ryohei Kuwatsuru; Hiroshi Toei; Ryusuke Murakami; Yoshihiko Saito; Atsushi Hirayama; Toyoaki Murohara; Akira Sato; Hideki Ishii; Tadateru Takayama; Makoto Watanabe; Kazuo Awai; Seitaro Oda; Takamichi Murakami; Yukinobu Yagyu; Nobuhiko Joki; Yasuhiro Komatsu; Takamasa Miyauchi; Yugo Ito; Ryo Miyazawa; Yoshihiko Kanno; Tomonari Ogawa; Hiroki Hayashi; Eri Koshi; Tomoki Kosugi; Yoshinari Yasuda
Journal:  Clin Exp Nephrol       Date:  2020-01       Impact factor: 2.801

9.  Serum osmolarity as a potential predictor for contrast-induced nephropathy following elective coronary angiography.

Authors:  Mehmet Kanbay; Dimitrie Siriopol; Elif Ozdogan; Baris Afsar; Lale A Ertuglu; Mihaela Grigore; Alan A Sag; Masanari Kuwabara; Miguel A Lanaspa; Alberto Ortiz; Richard J Johnson; Adrian Covic
Journal:  Int Urol Nephrol       Date:  2020-02-01       Impact factor: 2.370

10.  Rationale, design, and baseline characteristics of the Acetylcystein for Contrast-Induced nephropaThy (ACT) Trial: a pragmatic randomized controlled trial to evaluate the efficacy of acetylcysteine for the prevention of contrast-induced nephropathy.

Authors: 
Journal:  Trials       Date:  2009-06-04       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.